An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

NCT05038878 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Difficulty recruiting patients

Conditions

Mild Autonomous Cortisol Excess

Interventions

DRUG: Elagolix

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]